NO320839B1 - Isolert polypeptid, fremgangsmate for dets fremstilling, isolert nukleinsyremolekyl, isolert antistoff, antisensemolekyl, preparat, anvendelse av henholdsvis et polypeptid og et nukleinsyremolekyl, vertscelle samt vektor. - Google Patents

Isolert polypeptid, fremgangsmate for dets fremstilling, isolert nukleinsyremolekyl, isolert antistoff, antisensemolekyl, preparat, anvendelse av henholdsvis et polypeptid og et nukleinsyremolekyl, vertscelle samt vektor. Download PDF

Info

Publication number
NO320839B1
NO320839B1 NO19974035A NO974035A NO320839B1 NO 320839 B1 NO320839 B1 NO 320839B1 NO 19974035 A NO19974035 A NO 19974035A NO 974035 A NO974035 A NO 974035A NO 320839 B1 NO320839 B1 NO 320839B1
Authority
NO
Norway
Prior art keywords
seq
polypeptide
isolated
nucleic acid
amino acid
Prior art date
Application number
NO19974035A
Other languages
English (en)
Norwegian (no)
Other versions
NO974035D0 (no
NO974035L (no
Inventor
Nicholas Kim Hayward
Gunther Weber
Sean Grimmond
Magnus Nordenskjold
Catharina Larsson
Original Assignee
Amrad Operations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPN1457A external-priority patent/AUPN145795A0/en
Priority claimed from AUPN6647A external-priority patent/AUPN664795A0/en
Priority claimed from AUPN7274A external-priority patent/AUPN727495A0/en
Application filed by Amrad Operations Pty Ltd filed Critical Amrad Operations Pty Ltd
Publication of NO974035D0 publication Critical patent/NO974035D0/no
Publication of NO974035L publication Critical patent/NO974035L/no
Publication of NO320839B1 publication Critical patent/NO320839B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO19974035A 1995-03-02 1997-09-02 Isolert polypeptid, fremgangsmate for dets fremstilling, isolert nukleinsyremolekyl, isolert antistoff, antisensemolekyl, preparat, anvendelse av henholdsvis et polypeptid og et nukleinsyremolekyl, vertscelle samt vektor. NO320839B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPN1457A AUPN145795A0 (en) 1995-03-02 1995-03-02 A novel growth factor and a genetic sequence encoding same
AUPN6647A AUPN664795A0 (en) 1995-11-20 1995-11-20 A novel growth factor and a genetic sequence encoding same
AUPN7274A AUPN727495A0 (en) 1995-12-22 1995-12-22 A novel growth factor and a genetic sequence encoding same-II
PCT/AU1996/000094 WO1996027007A1 (fr) 1995-03-02 1996-02-22 Nouveau facteur de croissance et sequence genetique codant ce facteur

Publications (3)

Publication Number Publication Date
NO974035D0 NO974035D0 (no) 1997-09-02
NO974035L NO974035L (no) 1997-11-03
NO320839B1 true NO320839B1 (no) 2006-01-30

Family

ID=27157841

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19974035A NO320839B1 (no) 1995-03-02 1997-09-02 Isolert polypeptid, fremgangsmate for dets fremstilling, isolert nukleinsyremolekyl, isolert antistoff, antisensemolekyl, preparat, anvendelse av henholdsvis et polypeptid og et nukleinsyremolekyl, vertscelle samt vektor.

Country Status (15)

Country Link
US (1) US20070135344A1 (fr)
EP (1) EP0815221B1 (fr)
JP (2) JPH11500139A (fr)
KR (1) KR100414615B1 (fr)
CN (1) CN1194090C (fr)
AT (1) ATE252600T1 (fr)
BR (1) BR9607628A (fr)
CA (1) CA2214439C (fr)
DE (1) DE69630442T2 (fr)
ES (1) ES2206558T3 (fr)
FI (1) FI120153B (fr)
HU (1) HU223438B1 (fr)
NO (1) NO320839B1 (fr)
NZ (2) NZ301611A (fr)
WO (1) WO1996027007A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5928939A (en) 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
WO1996039421A1 (fr) * 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Facteur de croissance 3 de l'endothelium vasculaire humain
ES2202469T5 (es) 1995-09-08 2011-06-06 Genentech, Inc. Proteína relacionada con el vegf.
DE69638142D1 (de) 1995-09-29 2010-04-15 Univ Siena Regulierte Gene und ihre Verwendungen
AU1116297A (en) 1995-11-08 1997-05-29 Immunex Corporation Flk-1 binding protein
US6994989B1 (en) 1995-11-08 2006-02-07 Immunex Corp. FLK-1 binding proteins
EP1283268A3 (fr) 1996-08-23 2004-01-02 Ludwig Institute For Cancer Research Facteur recombinant de croissance de cellules vascularies endothéliales D (VEGF-D)
CN1260835A (zh) * 1997-04-25 2000-07-19 科莱特诺医疗公司 截短的vegf相关蛋白质
SG117417A1 (en) 1998-02-06 2005-12-29 Collateral Therpeutics Inc Variants of the angiogenic factor vascular endothelial cell growth factor: vegf
ATE556090T1 (de) 1998-11-10 2012-05-15 Ludwig Inst Cancer Res Verkürzter, von blutplättchen abstammender wachstumsfaktor d, dafür kodierendes dns und deren verwendung
US7105481B2 (en) 1998-11-10 2006-09-12 Ludwig Institute For Cancer Research Method for stimulating connective tissue growth or wound healing
DK1137773T3 (da) 1998-12-07 2008-12-08 Zymogenetics Inc Væsktfaktorhomolog ZVEGF3
US6783953B1 (en) 1998-12-22 2004-08-31 Janssen Pharmaceutica N.V. Vascular endothelial growth factor-X
AUPQ568100A0 (en) * 2000-02-16 2000-03-09 Amrad Operations Pty. Limited A method for producing recombinant molecules
AU2002228841C1 (en) 2000-12-07 2006-11-23 Sangamo Biosciences, Inc Regulation of angiogenesis with zinc finger proteins
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7981863B2 (en) * 2001-09-19 2011-07-19 Neuronova Ab Treatment of Parkinson's disease with PDGF
ATE553122T1 (de) 2005-02-28 2012-04-15 Sangamo Biosciences Inc Antiangiogene methoden und zusammensetzungen
CN100448892C (zh) * 2006-08-02 2009-01-07 中国人民解放军军事医学科学院基础医学研究所 抗肿瘤血管内皮生长因子受体vegf-r2抗原及其编码基因与应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5073492A (en) * 1987-01-09 1991-12-17 The Johns Hopkins University Synergistic composition for endothelial cell growth
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5219739A (en) * 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
US5338671A (en) * 1992-10-07 1994-08-16 Eastman Kodak Company DNA amplification with thermostable DNA polymerase and polymerase inhibiting antibody
EP0751992B1 (fr) * 1994-03-08 2005-11-09 Human Genome Sciences, Inc. Facteur 2 de croissance endotheliale vasculaire
US5607918A (en) * 1995-03-01 1997-03-04 Ludwig Institute For Cancer Research Vascular endothelial growth factor-B and DNA coding therefor
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor

Also Published As

Publication number Publication date
HU223438B1 (hu) 2004-07-28
NO974035D0 (no) 1997-09-02
CN1224464A (zh) 1999-07-28
FI973571A0 (fi) 1997-09-01
ATE252600T1 (de) 2003-11-15
EP0815221B1 (fr) 2003-10-22
HUP9800377A1 (hu) 1998-06-29
KR19980702702A (ko) 1998-08-05
NZ337634A (en) 2001-06-29
FI120153B (fi) 2009-07-15
US20070135344A1 (en) 2007-06-14
HK1002963A1 (en) 1998-09-30
WO1996027007A1 (fr) 1996-09-06
DE69630442D1 (de) 2003-11-27
JP2001037493A (ja) 2001-02-13
NZ301611A (en) 2000-02-28
EP0815221A1 (fr) 1998-01-07
NO974035L (no) 1997-11-03
FI973571L (fi) 1997-10-30
BR9607628A (pt) 1999-11-30
JPH11500139A (ja) 1999-01-06
EP0815221A4 (fr) 1998-12-09
ES2206558T3 (es) 2004-05-16
KR100414615B1 (ko) 2004-05-27
JP3683778B2 (ja) 2005-08-17
HUP9800377A3 (en) 2000-12-28
CN1194090C (zh) 2005-03-23
CA2214439A1 (fr) 1996-09-06
DE69630442T2 (de) 2004-08-19
CA2214439C (fr) 2002-12-17

Similar Documents

Publication Publication Date Title
NO320839B1 (no) Isolert polypeptid, fremgangsmate for dets fremstilling, isolert nukleinsyremolekyl, isolert antistoff, antisensemolekyl, preparat, anvendelse av henholdsvis et polypeptid og et nukleinsyremolekyl, vertscelle samt vektor.
DE69733204T3 (de) Neuartige vegf-ähnliche faktoren
Prasad et al. Complementary DNA cloning of a novel epithelial cell marker protein, HME1, that may be down-regulated in neoplastic mammary cells
DE69734359T2 (de) Rekombinanter vaskulärer endothelzellen wachstumsfaktor d (vegf-d)
DE69931178T2 (de) Ein dem vaskularen endothelen wachstumsfaktor verwandtes protein aus orf virus nz10 bindet und aktiviert den säuger vegf rezeptor-2
DE69534351T2 (de) Motorneuronlebenserhaltungsgen: ein Gen für spinale Muskelatrophie
EP1923465A1 (fr) Protéine inhibitrice du trajet du signal WNT
DE69833211T2 (de) Humanes persephin
AU707513B2 (en) A novel growth factor and a genetic sequence encoding same
US7160991B1 (en) Vascular endothelial growth factor polypeptides
DE69936192T2 (de) Menschliches stanniocalcin und seine verwendung zur hemmung der adipogenese
Cohen et al. Isolation and sequence analysis of two intermediate filament cDNA clones from fish optic nerve
HK1002963B (en) A novel growth factor and a genetic sequence encoding same
IE912281A1 (en) New protein with cell-differentiation or cell-formation¹ability and recombinant process for the production
PL185293B1 (pl) Izolowany polipeptyd, izolowana cząsteczka kwasu nukleinowego, sposób otrzymywania polipeptydu, cząsteczka antysensowna, środek farmaceutyczny, komórka gospodarza oraz wektor
AU713198B2 (en) Cloning, expression and uses of a novel secreted protein, F-spondin
AU1947900A (en) Cloning, expression and uses of a novel secreted protein F-spondin

Legal Events

Date Code Title Description
MK1K Patent expired